ENDOVALVE

About ENDOVALVE

Endovalve, founded in 2005, operated in the surgical devices industry with a focus on developing a novel system for mitral valve replacement. The company, which is now out of business, was headquartered in Princeton, New Jersey. Its core mission was to provide a less invasive treatment option for patients suffering from mitral regurgitation, a condition where the heart's mitral valve doesn't close properly.

The firm concentrated on creating a transcatheter mitral valve replacement system. This technology was designed to allow for a complete valve replacement through a minimally invasive procedure, thereby avoiding the significant risks associated with open-heart surgery, such as a sternotomy and cardiopulmonary bypass. The intended beneficiaries of this approach were patients who could receive treatment before their condition escalated to a critical state. This market is characterized by patients, often older or with other health conditions, who are considered poor candidates for traditional open-heart surgery. The procedure typically involves guiding a new, compressed valve to the heart via a catheter, often inserted through a blood vessel in the groin, and then expanding it into place.

Throughout its operation, Endovalve secured venture capital funding to support its research and development efforts. The company raised an initial $2.5 million in a Series A round in June 2006, followed by a Series B round of $7.52 million in February 2007, bringing its total funding to over $10 million. Despite these financial milestones and its work in a field with significant clinical need, the company ultimately ceased operations.